Study: A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF OP-1250 MONOTHERAPY VS STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2- ADVANCED OR METASTATIC BREAST CANCER FOLLOWING ENDOCRINE AND CDK 4/6 INHIBITOR THERAPY (OPERA-01)
Thank you for expressing your interest in a research study and for taking the time to provide your information.
By clicking 'Submit', your information will be shared with the research team. Typically a member of the research team will contact you within 5 to 7 business days.
Please understand that:
Thanks again. Volunteers such as yourself are at the core of our work.